Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. pharma Merck unit seeks Japan's approval of oral COVID drug

12/03/2021 | 04:28am EST

The Japanese arm of U.S. pharmaceutical giant Merck & Co. said Friday it has applied for state approval for the production and sale of an oral COVID-19 drug, which if granted could be the first such pill to be used in Japan.

MSD K.K. said in a press release that it is seeking the green light from the Ministry of Health, Labor and Welfare under a fast-track process for the Merck-developed molnupiravir, which prevents the virus from entering or multiplying in the body.

The Japanese government has already agreed with Merck on the procurement of 1.6 million doses and plans to make the orally-administered pill available by the end of the year. The drug, which can be taken at home, is regarded by Japan as vital to fighting the pandemic.

Clinical trial data show that patients given the drug within five days of developing coronavirus symptoms were 30 percent less likely to be hospitalized or die compared to those who were given a placebo, according to the Japanese subsidiary.

In an interim report on clinical trials across areas including Japan, Europe and the United States, Merck initially reported that the use of the oral drug halves the risk of hospitalization and death. But the percentage was revised downward after the firm increased the number of trial participants.

The United States, where approval of molnupiravir is currently being processed, is expected to allow the emergency use of the oral medicine for COVID-19 adult patients who are at risk of developing severe symptoms.

Britain on Nov. 4 became the first country in the world to approve use when it gave the green light for prescribing molnupiravir for people with mild or moderate symptoms and at least one risk factor for developing severe illness.

The British regulator does not recommend the use of the drug for pregnant people. The drug is not approved for children.

==Kyodo

© Kyodo News International, Inc., source Newswire

All news about MERCK & CO., INC.
01/28JPMorgan Adjusts Merck's Price Target to $95 From $100, Reiterates Overweight Rating
MT
01/28European Commission Approves Merck's KEYTRUDA as Adjuvant Therapy for Certain Patients ..
AQ
01/28MERCK : Molnupiravir Covid-19 Pill Effective Against Omicron in Lab Tests
DJ
01/28Merck Says Molnupiravir Active Against Omicron Variant in In Vitro Studies
MT
01/28Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27Merck & Co.'s Keytruda Wins EU Nod for Adjuvant Treatment of Kidney Cancer
MT
01/27Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
01/27Merck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
01/27European Commission Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Therapy for ..
BU
01/27European Commission Approves Merck’s KEYTRUDA« (pembrolizumab) as Adjuvant Therapy..
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 424 M - -
Net income 2021 11 938 M - -
Net Debt 2021 18 732 M - -
P/E ratio 2021 17,3x
Yield 2021 3,23%
Capitalization 204 B 204 B -
EV / Sales 2021 4,61x
EV / Sales 2022 3,87x
Nbr of Employees 73 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 80,90 $
Average target price 91,86 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.5.56%203 541
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960